These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 21460436)

  • 1. Targeting oligomers in neurodegenerative disorders: lessons from α-synuclein, tau, and amyloid-β peptide.
    Gadad BS; Britton GB; Rao KS
    J Alzheimers Dis; 2011; 24 Suppl 2():223-32. PubMed ID: 21460436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neurodegenerative conformational disease and its molecular bases].
    Li WW; Cai DF; Ren HM
    Sheng Li Ke Xue Jin Zhan; 2006 Apr; 37(2):97-102. PubMed ID: 16850610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Can prion-like propagation occur in neurodegenerative diseases?: in view of transmissible systemic amyloidosis].
    Yoshida K; Higuchi K; Ikeda S
    Brain Nerve; 2012 Jun; 64(6):665-74. PubMed ID: 22647474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of neurotoxic tau oligomers.
    Lasagna-Reeves CA; Castillo-Carranza DL; Guerrero-Muoz MJ; Jackson GR; Kayed R
    Biochemistry; 2010 Nov; 49(47):10039-41. PubMed ID: 21047142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins.
    Meredith SC
    Ann N Y Acad Sci; 2005 Dec; 1066():181-221. PubMed ID: 16533927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiprotein deposits in neurodegenerative disorders: our experience in the tissue brain bank of Navarra.
    Echávarri C; Caballero MC; Aramendía A; García-Bragado F; Tuñón T
    Anat Rec (Hoboken); 2011 Jul; 294(7):1191-7. PubMed ID: 21618706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protein aggregation and neurodegenerative disease.
    Ross CA; Poirier MA
    Nat Med; 2004 Jul; 10 Suppl():S10-7. PubMed ID: 15272267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunotherapy targeting misfolded proteins in neurodegenerative disease].
    Kanemaru K
    Brain Nerve; 2013 Apr; 65(4):469-74. PubMed ID: 23568995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease?
    Armstrong RA; Lantos PL; Cairns NJ
    Neuropathology; 2008 Aug; 28(4):351-65. PubMed ID: 18433435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein misfolding and neurodegeneration.
    Soto C; Estrada LD
    Arch Neurol; 2008 Feb; 65(2):184-9. PubMed ID: 18268186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid peptides and proteins in review.
    Harrison RS; Sharpe PC; Singh Y; Fairlie DP
    Rev Physiol Biochem Pharmacol; 2007; 159():1-77. PubMed ID: 17846922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic animal models of neurodegenerative diseases and their application to treatment development.
    Rockenstein E; Crews L; Masliah E
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1093-102. PubMed ID: 17869376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases.
    Choi ML; Gandhi S
    FEBS J; 2018 Oct; 285(19):3631-3644. PubMed ID: 29924502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
    Ciechanover A; Kwon YT
    Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeding and propagation of lesions in neurodegenerative diseases: a new paradigm.
    Duyckaerts C; Seilhean D; Sazdovitch V; Plu I; Delatour B; Potier MC
    Bull Acad Natl Med; 2015 Jun; 199(6):809-819. PubMed ID: 29901881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides.
    Gallardo G; Schlüter OM; Südhof TC
    Nat Neurosci; 2008 Mar; 11(3):301-8. PubMed ID: 18297066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of cellular prion protein in interneuronal amyloid transmission.
    Del Río JA; Ferrer I; Gavín R
    Prog Neurobiol; 2018; 165-167():87-102. PubMed ID: 29530723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide.
    Haass C; Selkoe DJ
    Nat Rev Mol Cell Biol; 2007 Feb; 8(2):101-12. PubMed ID: 17245412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Conformationally altered proteins cause neurodegenerative diseases].
    Ingelsson M; Nilsson L; Basun H; Aquilonius SM; Lannfelt L
    Lakartidningen; 2005 Nov 21-27; 102(47):3542-3, 3545-6, 3549 passim. PubMed ID: 16408392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble oligomers from a non-disease related protein mimic Abeta-induced tau hyperphosphorylation and neurodegeneration.
    Vieira MN; Forny-Germano L; Saraiva LM; Sebollela A; Martinez AM; Houzel JC; De Felice FG; Ferreira ST
    J Neurochem; 2007 Oct; 103(2):736-48. PubMed ID: 17727639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.